Login
Illumina NASDAQ: ILMN
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic analysis.
| Name | Illumina |
| Ticker | ILMN |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Price | 461.05 |
| 52W Low/High | 209.20 / 504.76 |
| Market cap | 67 B |
| 1Y Total Return |
70.79%
Strong |
| 1Y Volatility |
48.10%
Less Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic analysis.
Details
| Ticker | ILMN |
| Name | Illumina |
| ISIN | US4523271090 |
| CUSIP | 452327109 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) |
|
Share as of 2/24/21
| Close Price | 461.05 |
| 52W Low/High | 209.20 / 504.76 |
| Market cap | 67 B |
| 1Y Total Return |
70.79%
Strong |
| 1Y Volatility |
48.10%
Less Risk |
| Beta | 1.27 |
| PE (trailing) |
103.61
High |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 20.3% |
| Cash from Op. / Cur. Liabilities | 0.87 |
| Diluted Earnings / Share | 4.45 |
| ROE | 14.1% |
| ROIC | 16.3% |
| Price / Revenue | 21.1 |
| Price / Book | 14.5 |
| Price / CF | 63.2 |
| Current Ratio | 3.6 |
| Cur.Liabilities / Tot.Liabilities | 0.4 |
| Financial Leverage | 0.40 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
3,239
|
3,543
|
3,333
|
2,752
|
2,398
|
2,220
|
|
| Gross Profit |
2,203
|
2,467
|
2,300
|
1,826
|
1,666
|
1,549
|
|
| R&D |
682
|
647
|
623
|
546
|
504
|
401
|
|
| EBITDA |
1,092
|
1,370
|
1,174
|
1,284
|
770
|
757
|
|
| Operating Income |
580
|
985
|
883
|
606
|
587
|
613
|
|
| Net Income exc. Extra |
656
|
1,002
|
826
|
726
|
463
|
462
|
|
| per Share | |||||||
| Diluted avg Shares |
148
|
149
|
149
|
148
|
148
|
149
|
|
| EPS exc. Extra |
4.45
|
6.74
|
5.56
|
4.92
|
3.07
|
3.10
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
7,585
|
7,316
|
6,959
|
5,257
|
4,281
|
3,688
|
|
| Cash, Eq & Invt ShortTerm |
3,472
|
3,414
|
3,512
|
2,145
|
1,559
|
1,386
|
|
| Total Current Assets |
4,483
|
4,451
|
4,490
|
2,980
|
2,318
|
2,097
|
|
| Total Non-Current Assets |
3,102
|
2,865
|
2,469
|
2,277
|
1,963
|
1,591
|
|
| Intangibles |
1,039
|
969
|
1,016
|
946
|
1,019
|
1,026
|
|
| Total Liabilities |
2,891
|
2,703
|
3,114
|
2,508
|
2,011
|
1,839
|
|
| Total Current Liabilities |
1,244
|
665
|
1,804
|
746
|
705
|
610
|
|
| Long Term Debt |
1,647
|
2,038
|
1,310
|
1,762
|
1,306
|
1,229
|
|
| Shareholder equity |
4,694
|
4,613
|
3,758
|
2,749
|
2,197
|
1,849
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
1,080
|
1,051
|
1,142
|
875
|
779
|
786
|
|
| Depreciation |
187
|
188
|
179
|
156
|
141
|
127
|
|
| Cash from Investing |
-554
|
745
|
-1,813
|
-214
|
-515
|
-107
|
|
| Capex |
189
|
209
|
296
|
312
|
271
|
143
|
|
| Cash from Financing |
-766
|
-897
|
594
|
-176
|
-296
|
-545
|
|
| Stock Issued |
-675
|
-265
|
-155
|
-180
|
-202
|
-202
|
|
| Debt (LT) Issued |
0
|
-550
|
731
|
-4
|
-61
|
-245
|
|
| Free Cash Flow |
1,456
|
-213
|
1,562
|
188
|
391
|
79
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
20.3%
|
28.3%
|
24.8%
|
26.3%
|
18.9%
|
20.8%
|
|
| NCFO / Op.Income |
186.2%
|
106.7%
|
129.3%
|
144.4%
|
132.7%
|
128.2%
|
|
| Current Ratio |
3.6
|
6.7
|
2.5
|
4.0
|
3.3
|
3.4
|
|
| Financial Leverage D/E |
0.40
|
0.40
|
0.53
|
0.43
|
0.48
|
0.59
|
|
| Return on Capital Avg |
16.3%
|
23.7%
|
24.5%
|
14.3%
|
18.9%
|
21.2%
|
|
| Return on Shareholder Equity |
14.1%
|
23.9%
|
25.4%
|
29.3%
|
22.4%
|
27.9%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available